M. Pálácova

发表

Hereditary breast and ovarian cancer syndrome

S. Modesitt, K. Petráková, M. Pálácova, 2011, Definitions.

Hormonal therapy in premenopausal patients with SR-positive, HER2-negative breast cancer

M. Pálácova, 2019, Onkologie.

Abstract P4-22-02: Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) withBRCA1orBRCA2mutations and metastatic breast cancer

A. Jager, M. Robson, M. Friedlander, 2017 .

Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.

Sung-Bae Kim, W. Gradishar, N. Masuda, 2019, Journal of Clinical Oncology.

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Sung-Bae Kim, W. Gradishar, M. Yamaguchi, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic testing and prevention of hereditary cancer at the MMCI--over 10 years of experience.

L. Forétova, M. Navrátilová, M. Svoboda, 2010, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.

H. Wildiers, Yeon-Hee Park, M. Friedlander, 2020, The Lancet. Oncology.

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study

W. Gradishar, J. Garber, A. Jager, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Genetic and Preventive Services for Hereditary Breast and Ovarian Cancer in the Czech Republic

L. Forétova, M. Navrátilová, K. Petráková, 2006, Hereditary Cancer in Clinical Practice.

Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer

H. Wildiers, Yeon-Hee Park, M. Friedlander, 2019, Annals of Oncology.

MiR-34b is associated with clinical outcome in triple-negative breast cancer patients

R. Vyzula, P. Fabián, O. Slabý, 2012, Diagnostic Pathology.

[Li-Fraumeni syndrome].

K. Petráková, M. Pálácova, P. Plevova, 2009, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.

[Triple-negative breast cancer: analysis of patients diagnosed and/or treated at the Masaryk Memorial Cancer Institute between 2004 and 2009].

L. Slámová, A. Poprach, R. Vyzula, 2012, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.

[Hereditary breast and ovarian cancer syndrome].

K. Petráková, M. Pálácova, M. Schneiderová, 2020, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

R. Gelber, L. Pusztai, J. Baselga, 2012, The Lancet.

Lapatinib with trastuzumab for HER 2-positive early breast cancer ( NeoALTTO ) : a randomised , open-label , multicentre , phase 3 trial

R. Gelber, L. Pusztai, J. Baselga, 2012 .

Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial

M. Campone, S. Chatterjee, U. Brown-Glaberman, 2022, Breast Cancer Research and Treatment.

Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.

M. Svoboda, K. Petráková, M. Pálácova, 2019, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.

M. Svoboda, K. Petráková, M. Pálácova, 2016, Klinicka onkologie.

[Triple Negative Breast Cancer].

R. Vyzula, P. Fabián, M. Svoboda, 2015, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.

Ribociclib Plus Letrozole in Patients with Hormone Receptor-positive, HER2-negative Advanced Breast Cancer with No Prior Endocrine Therapy: Subgroup Safety Analysis from The Phase 3b CompLEEment-1 Trial

J. Beniak, S. Borstnar, E. Gal-Yam, 2022, Radiology and oncology.

Systemic treatment of breast cancer in young patients with a germline mutation in the BRCA1 and BRCA2 genes

M. Pálácova, 2023, Onkologie.

The impact of the 21-gene assay in the Czech Republic on adjuvant chemotherapy (CT) recommendations and costs in estrogen receptor positive (ER+) early stage breast cancer (ESBC) patients with grade 2 tumors and risk factors

K. Petráková, M. Pálácova, T. Svoboda, 2016 .

Anthracycline based chemotherapy decreases amplification status of Her-2/neu and topoisomerase II alpha genes in locally advanced breast cancer.

L. Dušek, R. Vyzula, K. Petráková, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Diagnostics of breast cancer in high-risk women - our own experience].

K. Petráková, M. Pálácova, M. Schneiderová, 2012, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

R. Gelber, L. Pusztai, J. Baselga, 2012, The Lancet.

[Hereditary Breast and Ovarian Cancer Syndrome].

K. Petráková, M. Pálácova, M. Schneiderová, 2016, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.